Cited by 355Treatment of Major DepressionMental Health Treatment and AccessPsychotherapy Techniques and Applications

The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.

Comparative Benefits and Harms of Second-Generation Antidepressants for Treating Major Depressive Disorder: An Updated Meta-analysis

Gartlehner, Gerald, Hansen, Richard A., Morgan, Laura C., Thaler, Kylie, Lux, Linda, Van Noord, Megan, Mager, Ursula, Thieda, Patricia, Gaynes, Bradley N., Wilkins, Tania, Strobelberger, Michaela, Lloyd, Stacey, Reichenpfader, Ursula, Lohr, Kathleen N.·2011·Annals of Internal Medicine

DOI 10.7326/0003-4819-155-11-201112060-00009

Open this paper in CoChat — free account

Abstract

BACKGROUND: Second-generation antidepressants dominate the management of major depressive disorder (MDD), but evidence on the comparative benefits and harms of these agents is contradictory. PURPOSE: To compare the benefits and harms of second-generation antidepressants for treating MDD in adults. DATA SOURCES: English-language studies from PubMed, Embase, the Cochrane Library, PsycINFO, and International Pharmaceutical Abstracts from 1980 to August 2011 and reference lists of pertinent review articles and gray literature. STUDY SELECTION: 2 independent reviewers identified randomized trials of at least 6 weeks' duration to evaluate efficacy and observational studies with at least 1000 participants to assess harm. DATA EXTRACTION: Reviewers abstracted data about study design and conduct, participants, and interventions and outcomes and rated study quality. A senior reviewer checked and confirmed extracted data and quality ratings. DATA SYNTHESIS: Meta-analyses and mixed-treatment comparisons of response to treatment and weighted mean differences were conducted on specific scales to rate depression. On the basis of 234 studies, no clinically relevant differences in efficacy or effectiveness were detected for the treatment of acute, continuation, and maintenance phases of MDD. No differences in efficacy were seen in patients with accompanying symptoms or in subgroups based on age, sex, ethnicity, or comorbid conditions. Individual drugs differed in onset of action, adverse events, and some measures of health-related quality of life. LIMITATIONS: Most trials were conducted in highly selected populations. Publication bias might affect the estimates of some comparisons. Mixed-treatment comparisons cannot conclusively exclude differences in efficacy. Evidence within subgroups was limited. CONCLUSION: Current evidence does not warrant recommending a particular second-generation antidepressant on the basis of differences in efficacy. Differences in onset of action and adverse events may be considered when choosing a medication. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.

Integrity signals

Registry

Crossref · 10.7326/0003-4819-155-11-201112060-00009

Cites

132 of 132 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Evaluating non-randomised intervention studies
Deeks, J., Dinnes, J., D'Amico, R., Sowden, A., Sakarovitch, C., Song, F., Petticrew, M., & Altman, D. (2003) · Health Technology Assessment · doi:10.3310/hta7270 · Cited by 2,907
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Combination of direct and indirect evidence in mixed treatment comparisons
Lu, G., & Ades, A. E. (2004) · Statistics in Medicine · doi:10.1002/sim.1875 · Cited by 2,172
Current methods of the U.S. Preventive Services Task Force
Harris, R., Helfand, M., Woolf, S. H., Lohr, K. N., Mulrow, C. D., Teutsch, S. M., & Atkins, D. C. (2001) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(01)00261-6 · Cited by 1,720
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
The Hamilton Depression Rating Scale: Has the Gold Standard Become a Lead Weight?
Bagby, R. M., Ryder, A. G., Schuller, D. R., & Marshall, M. B. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.12.2163 · Cited by 1,148
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
National Patterns in Antidepressant Medication Treatment
Olfson, M., & Marcus, S. C. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.81 · Cited by 730
Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications
Melander, H., Ahlqvist-Rastad, J., Meijer, G., & Beermann, B. (2003) · BMJ · doi:10.1136/bmj.326.7400.1171 · Cited by 634

Show all 131 references

Research works printed but not linked: 10

Bennie EH, 1995, J Clin Psychiatry, 56, 229
Alves C, 1999, Primary Care Psychiatry, 5, 57
Beasley CM, 1991, J Clin Psychiatry, 52, 294
McPartlin GM, 1998, Primary Care Psychiatry, 4, 127
Gagiano CA, 1993, Br J Clin Res, 4, 145
Baldwin DS, 1996, J Clin Psychiatry, 57, 46
Montejo AL, 2001, J Clin Psychiatry, 62, 10
Schöne W, 1993, J Clin Psychopharmacol, 13, 34S
Khazaie H, 2011, Neurosciences (Riyadh), 16, 42
Feighner JP, 1991, J Clin Psychiatry, 52, 329

Sorted by citations

The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and Meta‐analyses
IOANNIDIS, J. P. A. (2016) · The Milbank Quarterly · doi:10.1111/1468-0009.12210 · Cited by 1,483
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“It is important to note that there is considerable variability among antidepressants in the nature and severity of side-effects, and these also vary from one individual to another (Gartlehner et al., 2008, 2011).”
Background
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
How to Use an Article Reporting a Multiple Treatment Comparison Meta-analysis
Mills, E. J., Ioannidis, J. P. A., Thorlund, K., Schünemann, H. J., Puhan, M. A., & Guyatt, G. H. (2012) · JAMA · doi:10.1001/2012.jama.11228 · Cited by 365
Aerobic exercise for adult patients with major depressive disorder in mental health services: A systematic review and meta-analysis
Morres, I. D., Hatzigeorgiadis, A., Stathi, A., Comoutos, N., Arpin-Cribbie, C., Krommidas, C., & Theodorakis, Y. (2019) · Depression and Anxiety · doi:10.1002/da.22842 · Cited by 350
Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables
Vancampfort, D., Correll, C. U., Wampers, M., Sienaert, P., Mitchell, A. J., De Herdt, A., Probst, M., Scheewe, T. W., & De Hert, M. (2014) · Psychological Medicine · doi:10.1017/s0033291713002778 · Cited by 317
Citalopram versus other anti-depressive agents for depression
Cipriani, A., Purgato, M., Furukawa, T. A., Trespidi, C., Imperadore, G., Signoretti, A., Churchill, R. C., Watanabe, N., & Barbui, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006534.pub2 · Cited by 314
Resting-state cortico-thalamic-striatal connectivity predicts response to dorsomedial prefrontal rTMS in major depressive disorder
Salomons, T. V., Dunlop, K., Kennedy, S. H., Flint, A., Geraci, J., Giacobbe, P., & Downar, J. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.222 · Cited by 299
Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review
Wang, S.-M., Han, C., Bahk, W.-M., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2018) · Chonnam Medical Journal · doi:10.4068/cmj.2018.54.2.101 · Cited by 299
Nonpharmacologic Versus Pharmacologic Treatment of Adult Patients With Major Depressive Disorder: A Clinical Practice Guideline From the American College of Physicians
Qaseem, A., Barry, M. J., Kansagara, D., & for the Clinical Guidelines Committee of the American College of Physicians (2016) · Annals of Internal Medicine · doi:10.7326/m15-2570 · Cited by 279
A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?
Sanchez, C., Reines, E. H., & Montgomery, S. A. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000023 · Cited by 295
Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach
Chekroud, A. M., Gueorguieva, R., Krumholz, H. M., Trivedi, M. H., Krystal, J. H., & McCarthy, G. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0025 · Cited by 276
Molecular and anatomical organization of the dorsal raphe nucleus
Huang, K. W., Ochandarena, N. E., Philson, A. C., Hyun, M., Birnbaum, J. E., Cicconet, M., & Sabatini, B. L. (2019) · eLife · doi:10.7554/elife.46464 · Cited by 267
Fluoxetine versus other types of pharmacotherapy for depression
Magni, L. R., Purgato, M., Gastaldon, C., Papola, D., Furukawa, T. A., Cipriani, A., & Barbui, C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004185.pub3 · Cited by 255
ACOG Clinical Practice Guideline No. 5: Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum
ACOG Committee on Clinical Practice Guidelines–Obstetrics (2023) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000005202 · Cited by 252
WHAT IS THE THRESHOLD FOR A CLINICALLY RELEVANT EFFECT? THE CASE OF MAJOR DEPRESSIVE DISORDERS: Theoretical Review: Threshold for a Clinically Relevant Effect
Cuijpers, P., Turner, E. H., Koole, S. L., van Dijke, A., & Smit, F. (2014) · Depression and Anxiety · doi:10.1002/da.22249 · Cited by 242
The International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women
Clayton, A. H., Goldstein, I., Kim, N. N., Althof, S. E., Faubion, S. S., Faught, B. M., Parish, S. J., Simon, J. A., Vignozzi, L., Christiansen, K., et al. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.11.002 · Cited by 226
Hypoactive Sexual Desire Disorder: A Review of Epidemiology, Biopsychology, Diagnosis, and Treatment
Parish, S. J., & Hahn, S. R. (2016) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2015.11.009 · Cited by 236
Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis
Furukawa, T. A., Salanti, G., Atkinson, L. Z., Leucht, S., Ruhe, H. G., Turner, E. H., Chaimani, A., Ogawa, Y., Takeshima, N., Hayasaka, Y., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010919 · Cited by 214
Uncertainty in Treatment Rankings: Reanalysis of Network Meta-analyses of Randomized Trials
Trinquart, L., Attiche, N., Bafeta, A., Porcher, R., & Ravaud, P. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2521 · Cited by 202
Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis
Fiest, K. M., Walker, J. R., Bernstein, C. N., Graff, L. A., Zarychanski, R., Abou-Setta, A. M., Patten, S. B., Sareen, J., Bolton, J. M., Marriott, J. J., et al. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2015.10.004 · Cited by 198
Examining the role of neuroinflammation in major depression
Furtado, M., & Katzman, M. A. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.06.009 · Cited by 199
The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management
Montejo, A. L., Montejo, L., & Baldwin, D. S. (2018) · World Psychiatry · doi:10.1002/wps.20509 · Cited by 202
Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis
Amick, H. R., Gartlehner, G., Gaynes, B. N., Forneris, C., Asher, G. N., Morgan, L. C., Coker-Schwimmer, E., Boland, E., Lux, L. J., Gaylord, S., et al. (2015) · BMJ · doi:10.1136/bmj.h6019 · Cited by 181
Antidepressants and the placebo effect
Kirsch, I. (2014) · Zeitschrift für Psychologie · doi:10.1027/2151-2604/a000176 · Cited by 164
Sexual Dysfunction associated with Second-Generation Antidepressants in Patients with Major Depressive Disorder: Results from a Systematic Review with Network Meta-Analysis
Reichenpfader, U., Gartlehner, G., Morgan, L. C., Greenblatt, A., Nussbaumer, B., Hansen, R. A., Van Noord, M., Lux, L., & Gaynes, B. N. (2014) · Drug Safety · doi:10.1007/s40264-013-0129-4 · Cited by 160
Self-citation
Efficacy and Acceptability of Pharmacological Treatments for Depressive Disorders in Primary Care: Systematic Review and Network Meta-Analysis
Linde, K., Kriston, L., Rücker, G., Jamil, S., Schumann, I., Meißner, K., Sigterman, K. E., & Schneider, A. (2015) · The Annals of Family Medicine · doi:10.1370/afm.1687 · Cited by 160
Hippocampal volume and total cell numbers in major depressive disorder
Cobb, J. A., Simpson, J., Mahajan, G., Overholser, J. C., Jurjus, G., Dieter, L., Herbst, N. P., May, W., Rajkowska, G., & Stockmeier, C. A. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.10.020 · Cited by 151
An adaptationist perspective on the etiology of depression
Durisko, Z., Mulsant, B. H., & Andrews, P. W. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.09.032 · Cited by 140
The Depression Treatment Cascade in Primary Care: A Public Health Perspective
Pence, B. W., O’Donnell, J. K., & Gaynes, B. N. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0274-y · Cited by 133
Comparative Benefits and Harms of Antidepressant, Psychological, Complementary, and Exercise Treatments for Major Depression: An Evidence Report for a Clinical Practice Guideline From the American College of Physicians
Gartlehner, G., Gaynes, B. N., Amick, H. R., Asher, G. N., Morgan, L. C., Coker‐Schwimmer, E., Forneris, C. A., Boland, E., Lux, L. J., Gaylord, S. A., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1813 · Cited by 148
Sexual dysfunction associated with major depressive disorder and antidepressant treatment
Clayton, A. H., Haddad, S. E., Iluonakhamhe, J.-P., Martinez, C. C. P., & Schuck, A. E. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.951324 · Cited by 133
Nonpharmacologic and Pharmacologic Treatments of Adults in the Acute Phase of Major Depressive Disorder: A Living Clinical Guideline From the American College of Physicians
Qaseem, A., Owens, D. K., Etxeandia‐Ikobaltzeta, I., Tufte, J., Cross, J. T., & Wilt, T. J. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2056 · Cited by 135
Antidepressant-Induced Female Sexual Dysfunction
Lorenz, T. K., Rullo, J., & Faubion, S. S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.04.033 · Cited by 133
Systematic Review of Clinical Practice Guidelines for Failed Antidepressant Treatment Response in Major Depressive Disorder, Dysthymia, and Subthreshold Depression in Adults
MacQUEEN, G. M., Santaguida, P. L., Keshavarz, H., Jaworska, N., Levine, M., Beyene, J., & Raina, P. S. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716664885 · Cited by 130
Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity
Telles‐Correia, D., Barbosa, A., Cortez‐Pinto, H., Campos, C., Rocha, N. B. F., & Machado, S. E. D. C. (2017) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v8.i1.26 · Cited by 121
Fructo-oligosaccharides from Morinda officinalis remodeled gut microbiota and alleviated depression features in a stress rat model
Chi, L., Khan, I., Lin, Z., Zhang, J., Lee, S. M., Leong, W., Hsiao, W. L. W., & Zheng, Y. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.153157 · Cited by 124
Meta-analysis of the effectiveness of the Trier Social Stress Test in eliciting physiological stress responses in children and adolescents
Seddon, J. A., Rodriguez, V. J., Provencher, Y., Raftery-Helmer, J., Hersh, J., Labelle, P. R., & Thomassin, K. (2020) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2020.104582 · Cited by 117
Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction
Jacobsen, P. L., Mahableshwarkar, A. R., Chen, Y., Chrones, L., & Clayton, A. H. (2015) · The Journal of Sexual Medicine · doi:10.1111/jsm.12980 · Cited by 123
Management Strategies for Antidepressant-Related Sexual Dysfunction: A Clinical Approach
Montejo, A. L., Prieto, N., de Alarcón, R., Casado‐Espada, N. M., de la Iglesia, J., & Montejo, L. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101640 · Cited by 114
Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient
Oluboka, O. J., Katzman, M. A., Habert, J., McIntosh, D., MacQueen, G. M., Milev, R. V., McIntyre, R. S., & Blier, P. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx081 · Cited by 104
Barriers to access for Canadians who use cannabis for therapeutic purposes
Belle‐Isle, L., Walsh, Z., Callaway, R., Lucas, P., Capler, R., Kay, R., & Holtzman, S. (2014) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2014.02.009 · Cited by 104
There are no randomized controlled trials that support the United States Preventive Services Task Force guideline on screening for depression in primary care: a systematic review
Thombs, B. D., Ziegelstein, R. C., Roseman, M., Kloda, L. A., & Ioannidis, J. P. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-13 · Cited by 100
A Systematic Approach to Pharmacotherapy for Geriatric Major Depression
Mulsant, B. H., Blumberger, D. M., Ismail, Z., Rabheru, K., & Rapoport, M. J. (2014) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2014.05.002 · Cited by 105
Rational Use of Antidepressant Drugs
Fava, G. A. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000362803 · Cited by 95
Brain Serotonin Release Is Reduced in Patients With Depression: A [11C]Cimbi-36 Positron Emission Tomography Study With a d-Amphetamine Challenge
Erritzøe, D., Godlewska, B. R., Rizzo, G., Searle, G. E., Agnorelli, C., Lewis, Y. L., Ashok, A. H., Colasanti, A., Boura, I., Farrell, C. M., et al. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.10.012 · Cited by 91
Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction: Current Management Perspectives
Atmaca, M. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s185757 · Cited by 89
Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation
Jha, M. K., & Trivedi, M. H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010233 · Cited by 87
Risk factors for non-adherence to antidepressant treatment in patients with mood disorders
Cuevas, C. D. L., Peñate, W., & Sanz, E. J. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1582-9 · Cited by 94
Molecular, Functional, and Structural Imaging of Major Depressive Disorder
Zhang, K., Zhu, Y., Zhu, Y., Wu, S., Liu, H., Zhang, W., Xu, C., Zhang, H., Hayashi, T., & Tian, M. (2016) · Neuroscience Bulletin · doi:10.1007/s12264-016-0030-0 · Cited by 87
Sexual Dysfunction Due to Psychotropic Medications
Clayton, A. H., Alkis, A. R., Parikh, N., & Votta, J. G. (2016) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2016.04.006 · Cited by 76
Second-Generation Antidepressants and Hyponatremia Risk: A Population-Based Cohort Study of Older Adults
Gandhi, S., Shariff, S. Z., Al‐Jaishi, A. A., Reiss, J. P., Mamdani, M., Hackam, D. G., Li, L., McArthur, E., Weir, M. A., & Garg, A. X. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.08.020 · Cited by 76
Initial severity of depression and efficacy of cognitive–behavioural therapy: Individual-participant data meta-analysis of pill-placebo-controlled trials
Furukawa, T. A., Weitz, E. S., Tanaka, S., Hollon, S. D., Hofmann, S. G., Andersson, G., Twisk, J., DeRubeis, R. J., Dimidjian, S., Hegerl, U., et al. (2017) · British Journal of Psychiatry · doi:10.1192/bjp.bp.116.187773 · Cited by 73
Antidepressant drugs and sexual dysfunction
Baldwin, D. S., & Foong, T. (2013) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.112.110650 · Cited by 73
Efficacy of New Generation Antidepressants: Differences Seem Illusory
Re, A. C. D., Spielmans, G. I., Flückiger, C., & Wampold, B. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063509 · Cited by 73
Is There Anything Really Novel on the Antidepressant Horizon?
Murrough, J. W., & Charney, D. S. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0321-8 · Cited by 70
A meta-analysis of lipid peroxidation markers in major depression
Lanctôt, K. L., Mazereeuw, G., Herrmann, N., Andreazza, A. C., & Khan, M. M. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s89922 · Cited by 69
Specificity profile of venlafaxine and sertraline in major depression: metaregression of double-blind, randomized clinical trials
Gibiino, S., Marsano, A., & Serretti, A. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000746 · Cited by 68
Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials
Hengartner, M. P., Jakobsen, J. C., Sørensen, A., & Plöderl, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229381 · Cited by 70
Effects of sulforaphane in the central nervous system
Huang, C., Wu, J., Chen, D., Jin, J., Wu, Y. H., & Chen, Z. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.03.010 · Cited by 71
Ketamine may exert antidepressant effects via suppressing NLRP3 inflammasome to upregulate AMPA receptors
Li, J., Liu, L.-L., Su, W., Wang, B., Zhang, T., Zhang, Y., & Jiang, C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.11.022 · Cited by 68
Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System
Sussman, M., O’sullivan, A. K., Shah, A., Olfson, M., & Menzin, J. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.7.823 · Cited by 65
Vortioxetine for depression in adults
Koesters, M., Ostuzzi, G., Guaiana, G., Breilmann, J., & Barbui, C. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011520.pub2 · Cited by 69
COMPARATIVE EFFECTIVENESS OF SECOND-GENERATION ANTIDEPRESSANTS FOR ACCOMPANYING ANXIETY, INSOMNIA, AND PAIN IN DEPRESSED PATIENTS: A SYSTEMATIC REVIEW
Thaler, K. J., Morgan, L. C., Noord, M. V., Gaynes, B. N., Hansen, R. A., Lux, L. J., Krebs, E. E., Lohr, K. N., & Gartlehner, G. (2012) · Depression and Anxiety · doi:10.1002/da.21951 · Cited by 64
Antidepressant-induced sexual dysfunction during treatment with fluoxetine, sertraline and trazodone; a randomized controlled trial
Khazaie, H., Rezaie, L., Payam, N. R., & Najafi, F. (2014) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2014.10.010 · Cited by 61
Impact of Antidepressant Drugs on Sexual Function and Satisfaction
Baldwin, D. S., Manson, C., & Nowak, M. (2015) · CNS Drugs · doi:10.1007/s40263-015-0294-3 · Cited by 64
Dopamine dysregulation hypothesis: the common basis for motivational anhedonia in major depressive disorder and schizophrenia?
Szczypiński, J., & Gola, M. K. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0091 · Cited by 62
Insomnia and Somnolence Associated With Second-Generation Antidepressants During the Treatment of Major Depression
Alberti, S., Chiesa, A., Andrisano, C., & Serretti, A. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000329 · Cited by 60
What matters to patients? A systematic review of preferences for medication-associated outcomes in mental disorders
Eiring, Ø., Landmark, B. F., Aas, E., Salkeld, G., Nylenna, M., & Nytrøen, K. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-007848 · Cited by 57
The Isoxazole Ring and Its N‐Oxide: A Privileged Core Structure in Neuropsychiatric Therapeutics
Pairas, G., Perperopoulou, F., Tsoungas, P. G., & Varvounis, G. (2017) · ChemMedChem · doi:10.1002/cmdc.201700023 · Cited by 57
The SUBITO-DE study: sexual dysfunction in newly diagnosed type 2 diabetes male patients.
Corona, G., Giorda, C. B., Cucinotta, D., Guida, P., & Nada, E. (2013) · PubMed · doi:10.3275/8969 · Cited by 55
Reducing Dropout in Treatment for Depression: Translating Dropout Predictors Into Individualized Treatment Recommendations
Zilcha-Mano, S., Keefe, J. R., Chui, H., Rubin, A., Barrett, M. S., & Barber, J. P. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10081 · Cited by 55
The efficacy of paroxetine and placebo in treating anxiety and depression: a meta-analysis of change on the hamilton rating scales
Sugarman, M. A., Loree, A. M., Baltes, B. B., Grekin, E. R., & Kirsch, I. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106337 · Cited by 55
Screening for Anxiety in Adolescent and Adult Women: A Recommendation From the Women's Preventive Services Initiative
Gregory, K. D., Chelmow, D. P., Nelson, H. D., Niel, M. S. V., Conry, J. A., García, F., Kendig, S. M., O’Reilly, N., Qaseem, A., Ramos, D., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0580 · Cited by 55
Evidence Map of Yoga for Depression, Anxiety, and Posttraumatic Stress Disorder
Duan-Porter, W., Coeytaux, R. R., McDuffie, J. R., Goode, A. P., Sharma, P., Mennella, H., Nagi, A., & Williams, J. W. (2016) · Journal of Physical Activity and Health · doi:10.1123/jpah.2015-0027 · Cited by 53
The Emperor’s New Drugs: Medication and Placebo in the Treatment of Depression
Kirsch, I. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-44519-8_16 · Cited by 55
Comparative Safety of Pharmacologic Treatments for Persistent Depressive Disorder: A Systematic Review and Network Meta-Analysis
Meister, R., von Wolff, A., Mohr, H., Härter, M. C., Nestoriuc, Y., Hölzel, L. P., & Kriston, L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153380 · Cited by 54
Predicting Barriers to Treatment for Depression in a U.S. National Sample: A Cross-Sectional, Proof-of-Concept Study
Chekroud, A. M., Foster, D. F., Zheutlin, A. B., Gerhard, D. M., Roy, B., Koutsouleris, N., Chandra, A., Esposti, M. D., Subramanyan, G., Gueorguieva, R. V., et al. (2018) · Psychiatric Services · doi:10.1176/appi.ps.201800094 · Cited by 51
The novel and potent anti-depressive action of triptolide and its influences on hippocampal neuroinflammation in a rat model of depression comorbidity of chronic pain
Hu, X., Dong, Y., Jin, X., Zhang, C., Zhang, T., Zhao, J., Shi, J., & Li, J. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.03.005 · Cited by 48
Adverse event methods were heterogeneous and insufficiently reported in randomized trials on persistent depressive disorder
Meister, R., von Wolff, A., Mohr, H., Nestoriuc, Y., Härter, M. C., Hölzel, L. P., & Kriston, L. (2015) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2015.10.007 · Cited by 44
Nonpharmacologic and Pharmacologic Treatments of Adult Patients With Major Depressive Disorder: A Systematic Review and Network Meta-analysis for a Clinical Guideline by the American College of Physicians
Gartlehner, G., Dobrescu, A. I., Chapman, A. L., Toromanova, A., Emprechtinger, R., Persad, E., Affengruber, L., Pieh, C., Klerings, I., & Wagner, G. (2023) · Annals of Internal Medicine · doi:10.7326/m22-1845 · Cited by 48
Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder
Robison, R. J., Barrow, R., Conant, C., Foster, E., Freedman, J. M., Jacobsen, P. L., Jemison, J., Karas, S. M., Karlin, D. R., Solomon, T. M., et al. (2025) · JAMA · doi:10.1001/jama.2025.13481 · Cited by 44
Personalized Psychiatry and Depression: The Role of Sociodemographic and Clinical Variables
Perna, G., Alciati, A., Daccò, S., Grassi, M., & Caldirola, D. (2020) · Psychiatry Investigation · doi:10.30773/pi.2019.0289 · Cited by 47
Differentially expressed genes related to major depressive disorder and antidepressant response: genome-wide gene expression analysis
Woo, H. I., Lim, S.-W., Myung, W., Kim, D. K., & Lee, S.-Y. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0123-0 · Cited by 42
Liver Safety Assessment: Required Data Elements and Best Practices for Data Collection and Standardization in Clinical Trials
Avigan, M., Bjornsson, E. S., Pasanen, M., Cooper, C. K., Andrade, R. J., Watkins, P. B., Lewis, J. H., & Merz, M. (2014) · Drug Safety · doi:10.1007/s40264-014-0183-6 · Cited by 43
Comparing Bona Fide Psychotherapies of Depression in Adults with Two Meta-Analytical Approaches
Braun, S. R., Gregor, B., & Tran, U. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068135 · Cited by 41
A Review of Antidepressant Therapy in Primary Care
Kennedy, S. H. (2013) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.12r01420 · Cited by 41
Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials
Bradley, A. J., & Lenox‐Smith, A. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113494937 · Cited by 42
Cumulative Antidepressant Use and Risk of Dementia in a Prospective Cohort Study
Heath, L., Gray, S. L., Boudreau, D. M., Thummel, K., Edwards, K. L., Fullerton, S. M., Crane, P. K., & Larson, E. B. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15508 · Cited by 41
Patients’ Perspectives on Psychiatric Pharmacogenetic Testing
Liko, I., Lai, E., Griffin, R. J., Aquilante, C. L., & Lee, Y. M. (2020) · Pharmacopsychiatry · doi:10.1055/a-1183-5029 · Cited by 40
A review of current evidence for vilazodone in major depressive disorder
Wang, S., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C. (2013) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2013.794245 · Cited by 41
Historic psychedelic drug trials and the treatment of anxiety disorders.
Weston, N. M., Gibbs, D., Bird, C. I. V., Daniel, A., Jelen, L. A., Knight, G., Goldsmith, D., Young, A. H., & Rucker, J. J. (2020) · Depression and Anxiety · doi:10.1002/da.23065 · Cited by 38
A comprehensive review and meta-analysis of neurological side effects related to second-generation antidepressants in individuals with major depressive disorder
Zhou, Q., Li, X., Yang, D., Xiong, C., & Xiong, Z. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114431 · Cited by 42
Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: A double-blind, randomized pilot study
Franco-Chaves, J. A., Mateus, C. F., Luckenbaugh, D. A., Martinez, P. E., Mallinger, A. G., & Zarate, C. A. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.02.003 · Cited by 39
Left dorsolateral prefrontal transcranial magnetic stimulation (TMS): Sleep factor changes during treatment in patients with pharmacoresistant major depressive disorder
Rosenquist, P. B., Krystal, A. D., Heart, K. L., Demitrack, M. A., & McCall, W. V. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.09.011 · Cited by 38
Adverse effects and treatment satisfaction among online users of four antidepressants
Hughes, S., Lacasse, J. R., Fuller, R. R., & Spaulding‐Givens, J. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.05.021 · Cited by 38
What Is New about New Antidepressants?
Dubovsky, S. L. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000488945 · Cited by 37
Comparative Benefits and Harms of Complementary and Alternative Medicine Therapies for Initial Treatment of Major Depressive Disorder: Systematic Review and Meta-Analysis
Asher, G. N., Gartlehner, G., Gaynes, B. N., Amick, H. R., Forneris, C. A., Morgan, L. C., Coker‐Schwimmer, E., Boland, E., Lux, L. J., Gaylord, S. A., et al. (2017) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2016.0261 · Cited by 37

Authors: Gartlehner, G., Hansen, R. A., Morgan, L. C., Thaler, K., Lux, L., Van Noord, M., Mager, U., Thieda, P., Gaynes, B. N., Wilkins, T., Strobelberger, M., Lloyd, S., Reichenpfader, U., & Lohr, K. N.
Affiliations: University of North Carolina at Chapel Hill (US)
From Danube University, Krems, Austria; Auburn University, Auburn, Alabama; RTI International, Research Triangle Park, North Carolina; the University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; and the Ludwig Boltzmann Institute for Health Promotion Research, Vienna, Austria.
ORCID: Gartlehner, Gerald
Hansen, Richard A.
Morgan, Laura C.
Thaler, Kylie
Lux, Linda
Gaynes, Bradley N.
Reichenpfader, Ursula
Lohr, Kathleen N.
Venue: Annals of Internal Medicine
Publisher: American College of Physicians
Published: 2011-12-06
Volume: 155
Issue: 11
Pages: 772-785
ISSN: 0003-4819 (ISSN-L)
1539-3704
DOI: 10.7326/0003-4819-155-11-201112060-00009
OpenAlex: W2082270426
Cited by: 355
References: 131
Citations by year: 2026: 13 · 2025: 17 · 2024: 15 · 2023: 22 · 2022: 23 · 2021: 13 · 2020: 23 · 2019: 20 · 2018: 34 · 2017: 20 · 2016: 35 · 2015: 32 · 2014: 36 · 2013: 29 · 2012: 23
FWCI: 3.51
Type: journal article
Language: en
Open access: closed
Licence: www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations: Annals of Internal Medicine (publishedVersion)
PubMed (publishedVersion)
Annals of Internal Medicine
Funders: U.S. Public Health Service (290200710056I#2)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
Keywords: second-generation antidepressants, major depressive disorder, antidepressant efficacy, antidepressant side effects, onset of action, health-related quality of life, maintenance therapy, continuation treatment, acute treatment
MeSH terms: Delayed-Action Preparations, Major Depressive Disorder, Humans, Recurrence, Remission Induction, Sexual Dysfunction, Physiological, Treatment Outcome, Antidepressive Agents, Second-Generation, Comparative Effectiveness Research, Suicidal Ideation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Comparative Benefits and Harms of Second-Generation Antidepressants for Treating Major Depressive Disorder: An Updated Meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks